



HAL
open science

Immunosorbents in microextraction

Valérie Pichon, Audrey Combès, Nathalie N. Delaunay

► **To cite this version:**

Valérie Pichon, Audrey Combès, Nathalie N. Delaunay. Immunosorbents in microextraction. Trends in Analytical Chemistry, 2019, 113, pp.246-255. 10.1016/j.trac.2019.02.016 . hal-02093834

HAL Id: hal-02093834

<https://hal.sorbonne-universite.fr/hal-02093834>

Submitted on 9 Apr 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

3
4 **Immunsorbents in microextraction**

5
6 Valérie Pichon*^{1,2}, Audrey Combès¹, Nathalie Delaunay²

7
8 1- Dept of Analytical, Bioanalytical Sciences and Miniaturization (LSABM), CNRS (UMR
9 CBI 8231) , ESPCI Paris, PSL University, 10 rue Vauquelin, 75 231 Paris Cedex 05,
10 France

11 2- Sorbonne Université, 4 Place Jussieu, 75005 Paris, France

12
13 Corresponding author: Valérie Pichon, valerie.pichon@espci.fr, +33140794772

14 Corresponding author institution: LSABM, ESPCI Paris, 10 rue Vauquelin, 75005 Paris, France.

15
16 **Abstract**

17 Trace analysis of target compounds from complex samples requires often a step of purification
18 and of preconcentration before the chromatographic separation. Immunoaffinity sorbents
19 functionalized with antibodies specific to the molecule(s) of interest appear as powerful tools
20 for their selective extraction to obtain more reliable and sensitive quantitative analysis.
21 Indeed, the high specificity and affinity of the antigen-antibody interactions allow an efficient
22 and selective clean-up with high enrichment factors.

23 Considering the cost of antibodies, the miniaturization of these sorbents presents a large
24 interest as it combines the advantages of the miniaturization such as the reduction of solvent
25 consumption and the application of the devices to reduced sample volumes while keeping
26 high enrichment factors with the high selectivity provided by the antibodies during the
27 extraction process. The objective of this review is to present the developments proposed
28 these last years in the field of microextraction methods involving antibodies.

29
30 **Key-words:** immunoaffinity; miniaturization; extraction; solid-phase microextraction; in-tube
31 solid-phase extraction; dispersive extraction; monolith

32
33 **Abbreviations**

34 Ab: antibody ; AFP: α -fetoprotein; APMH: aminopropylmethacrylamide hydrochloride; APTES:
35 (3-aminopropyl)-triethoxysilane; [BMIM]BF₄: 1-butyl-3-methyl-imidazolium
36 tetrafluoroborate; CE: capillary electrophoresis; COC: cyclic olefin copolymer; GMA: glycidyl
37 methacrylate; GMM: glycerylmethacrylate; CSF: cerebrospinal fluids; DGS: diglycerylsilane;
38 dSPE: dispersive solid-phase extraction; EDA: ethylenediamide; EDMA: ethylene
39 dimethacrylate; EF : enrichment factor; ET: epitestosterone; Fabs: antibodies fragments; Fluo:
40 fluorescence; GC: gas chromatography; GMA: glycidylmethacrylate; GMM:
41 glycerylmethacrylate; GNP: gold nanoparticle; GTD: glutaraldehyde; HEMA: 2-hydroxyethyl
42 methacrylate; IgG: immunoglobuline G; IA: immunoaffinity; IS: immunosorbent; IT: in-tube;
43 IMS: ion mobility spectrometry; LIF: laser induced fluorescence; LC: liquid chromatography;
44 LP: lipoprotein; LR: linear range; mAbs: monoclonal antibodies; MIP: molecularly imprinted
45 polymer; MS: mass spectrometry; NHS: N-hydroxysuccinimide; NP: nanoparticle; OS:
46 oligosorbent; pAbs: polyclonal antibodies; PBP2a: penicillin binding protein 2a; PBS:
47 phosphate buffer saline; PEG: polyethyleneglycol; PEGDA: polyethyleneglycoldiacrylate;

48 PETIA: particle-enhanced turbidimetric assay; PMMA: polymethylmethacrylate; RE: recovery
49 of extraction; RSD: relative standard deviation; SPE: solid-phase extraction; SPME: solid-phase
50 microextraction; SSMCC: sulfosuccinimidyl-4-(N-maleimido-methyl) cyclohexane-1 –
51 carboxylate; TEOS: tetraethyl orthosilicate; UHPLC: ultra-high performance LC; VDA: 2-vinyl-4,
52 4-dimethylazlactone

53

54

55 **1- Introduction**

56


57 These recent years, the evolution of the instrumentation in terms of separation and detection
58 allowed a real improvement of sensitivity and analysis time. However, the analysis of target
59 analytes in complex samples requires powerful specific analytical tools to provide reliable
60 results. The specificity of an analytical method can be obtained by efficient separation
61 methods but also by their hyphenation with a specific detection such as mass spectrometry
62 (MS). Indeed, the specificity of the MS signal is particularly helpful to confirm the presence of
63 a compound in a complex sample, particularly when the peak capacity of the separation is not
64 sufficient, as it is often the case for complex samples. However, matrix components may
65 interfere during the ionization process in the MS source thus affecting the reliability of the
66 target analytes quantification. The removal of interfering compounds during sample
67 pretreatment can be ensured by introducing a sample-clean-up step using sorbents providing
68 a selective retention mechanism. For example, restricted access media, large particles
69 sorbents or monoliths were proposed for the removal of macromolecules [1], and mixed-
70 mode sorbents for the extraction of acidic or basic compounds from real samples such as
71 biological fluids or environmental waters [2]. To go further in term of selectivity, sorbents
72 providing a retention based on a molecular recognition mechanism were developed, such as
73 molecularly imprinted polymers (MIPs) [3,4], aptamers-based sorbents, namely oligosorbents
74 (OSs) [5] and antibodies-based sorbents, namely immunosorbents (ISs) [6,7].

75 If MIPs and especially OSs are quite new sorbents, immunosorbents (ISs) were developed since
76 the pioneer work of Farjam [8] in the nineties and numerous ISs are commercially available
77 mainly for the extraction of pesticides, toxins or drugs from foodstuff [6]. Indeed, their use for
78 the trace analysis of mycotoxins in foodstuff is today widely implemented in control laboratory
79 [7]. In most of the cases, antibodies (Abs) are covalently grafted onto activated Sepharose gel
80 or activated silica to be packed between two frits into 1-6 mL disposable cartridges that can
81 contain tens or even hundreds of milligrams of IS to be used as conventional solid-phase
82 extraction (SPE) sorbents. Indeed, an immunoextraction sequence consists in the percolation
83 of the sample through the IS cartridge after a conditioning step, washing of the IS to remove
84 the residual interfering compounds, and elution of the target analyte(s) by disrupting the
85 antigen-antibody interactions.

86 The easy automation of the on-line coupling of SPE with liquid chromatography (LC) makes
87 this technique powerful by replacing conventional SPE sorbent with the IS. For this, tens
88 milligrams of IS particles are packed in a small size-precolum coupled on-line with the LC
89 system [7]. This decrease in the size of the precolum compared to that of the cartridges also
90 allows reducing the cost of the ISs by decreasing the amount of immobilized antibodies while
91 maintaining method performance.

92 In recent years, many researches were devoted to the development of miniaturized extraction
93 devices with the objectives to limit the reagents consumption, to adapt the extraction devices
94 and to reduced sample volume [9,10]. In this field, the use of a fiber as extraction device in

95 solid-phase microextraction (SPME) has proven its potential since more than 30 years [11,12].
 96 Since this development, other formats have been proposed such as dispersive SPE based on
 97 micro- and nano-sorbents [13] including or not a magnetic core [14], in-tube SPME involving
 98 conventional sorbents such as polymers but also new types of sorbent or functionalization
 99 such as carbon nanotubes, metal organic frameworks, ionic liquids, surfactants or titanium
 100 dioxide [15]. The reduction of the size of the devices is particularly interesting when expensive
 101 reagents such as antibodies have to be used. This explains some recent developments related
 102 to the introduction of antibodies in such microextraction devices. In addition, in order to
 103 integrate those miniaturized immunoextraction devices within miniaturized analytical
 104 methods, such as capillary electrophoresis (CE) and nanoLC, new approaches were proposed
 105 that mainly consist in the synthesis of monoliths further grafted with antibodies. This also
 106 allows the integration of ISs into chips. The aim of this review is to present the different
 107 approaches reported for the development of miniaturized ISs (see Figure 1) and their potential
 108 for the extraction of target analytes from complex samples.
 109




110
 111 **Figure 1:** Different approaches reported in literature for the development of miniaturized ISs: (A) dispersive solid-
 112 phase extraction (dSPE); (B) solid-phase micro-extraction (SPME); (C) In-tube solid-phase micro-extraction (IT-
 113 SPME), monolith (D) integrated at the end of a capillary for its coupling with CE, (E) in a capillary coupled to
 114 nanoLC or (F) in the channel of a chip.
 115
 116
 117

118 2- Dispersive solid phase extraction

119
 120 In dispersive SPE (dSPE), the extraction is carried out by introducing the sorbent directly in the
 121 sample instead of percolating the sample through the sorbent packed in a cartridge. The use
 122 of nanoparticles (in the order of tens of nanometers instead of tens of micrometers) presents
 123 some advantages, such as the reduction of the amount of antibodies required, their
 124 application to reduced volume of samples and above all a large specific surface area and then
 125 high adsorption capacity thus favoring high enrichment factors [16]. Particles are first
 126 dispersed in the sample to interact with the analyte (Figure 1A). After a sufficient extraction

127 time under stirring, the particles are recovered mainly by centrifugation [17] or by a magnetic
128 field (when using particles with a magnetic cores) [18–20] to be further introduced into a
129 suitable desorption solvent. In the reported works, the extraction procedure takes from 20
130 min to overnight and some of the procedures include a washing step before the elution to
131 ensure an optimal selectivity [17,18]. Therefore, if this approach allows to reduce sample
132 volumes and antibodies consumption, extraction methods remain quite time consuming.
133 Different types of particles with immobilized antibodies have been already prepared to
134 develop dSPE procedure. These studies are summarized in Table 1. The extraction particles
135 were mainly prepared by the covalent immobilization of antibodies. When preparing such
136 nanosorbents, as mentioned by Haller *et al* [17], antibodies surface coverage is strongly
137 dependent on the size of the NPs, the immobilization strategy, reaction conditions, as well as
138 the concentration of Abs in the reaction mixture. As a result, this group recently proposed a
139 careful optimization of the immobilization conditions by exploring distinct random and
140 oriented immobilization of Abs onto gold nanoparticles (GNPs), such as (i) direct adsorptive
141 attachment on the NP surface, (ii) covalent bonding by amide coupling of Abs to carboxy-
142 terminated-pegylated NPs, (iii) oriented immobilization via oxidized carbohydrate moiety of
143 the Ab on hydrazide-derivatized NPs and (iv) cysteine-tagged protein A-bonded NPs [17]. It
144 was observed that an oriented immobilization via Protein A was the most advantageous
145 strategy in terms of colloidal stability, saturation capacity, and extraction recovery. This GNP-
146 Ab conjugate was chemically very stable unlike the IS NPs resulting from the adsorption
147 strategy. Moreover, it was also mentioned that no bleeding was observed for the conjugates
148 with pegylated spacers which could have interfered with the mass spectrometry (MS)
149 detection. To limit the saturation of the sorbent caused by steric hindrance due to the large
150 antibody size, Qiu *et al.* proposed to immobilize half-antibodies, obtained by splitting in two
151 the Abs using 2-aminoethanethiol that disrupts disulfide bonds between the two heavy chains
152 [18]. The use of half antibodies with reduced SH moiety also allows an easy grafting of the
153 antibodies to gold NPs via Au-S bonds. The grafting yield was then estimated to 1 mg of half
154 Abs for 10 mg of NPs.

155 Immuno-dSPE was applied to sample volumes ranging from 10 μ l to 20 ml (i. e. 3 orders of
156 magnitude), depending on the expected enrichment factor, with resulting extraction times
157 between 15 min to overnight and recoveries higher than 80% in all cases. The
158 immunoextraction was associated either to a separation method or directly to a detection
159 mode such as fluorescence (Fluo) or ion mobility spectrometry (IMS) since the antibody
160 selectivity allows the removal of interfering compounds, thus rendering the use of a
161 separation method not necessary. This removal of interfering compounds is illustrated by the
162 comparison of chromatograms reported in Figure 2 and obtained for a urine sample analyzed
163 without (Figure 2a) or with the use of half antibodies grafted on magnetic NPs (MNPs) (Figure
164 2b) applied to the extraction of epitestosterone (ET), the absence of Abs on MNPs preventing
165 the extraction of ET (Figure 2c) [18]. The contribution of non specific interactions mainly
166 caused by the nature of the sorbent was not studied in detail in these works related to dSPE,
167 but one study observed a low loading capacity of 10% of a structural analog compared to the
168 binding capacity of the targeted lipoprotein, which was considered by the authors as a
169 measure of the non specific events [17]. It is worthwhile to notice that the reusability of the
170 IS particles was studied by some authors that reported the possibility to used them 5 [20] to
171 15 times [19] without observing any loss of performance.



174
175
176
177
178
179
180
181

Figure 2: HPLC analysis of epitestosterone (ET) in a urine sample spiked with ET at 100 ng/ml (a) without immunoextraction-based dSPE, (b) with immunoextraction-based dSPE using Fe₃O₄@Au MNPs grafted with anti-ET Abs, and (c) dSPE using bare Fe₃O₄@Au MNPs. With the permission from Elsevier [18].

Table 1: Application of immunoaffinity-based dispersive SPE.

Target	Sam ple	Extracti on sorbent	Antibody grafting	Method	Analytic al method	Method performan ce	RE F
Epitestoster one	Urine (20 ml)	Fe ₃ O ₄ - Au NPs (50 nm)	covalent grafting through Au-S bonds of half mAb (obtained by reduction of native disulfide bonds between the two heavy chains)	Incubation, washing (3x, water), desorption (3x, MeOH), 1 h for the whole procedure	HPLC- UV	RE: 92- 103% (urine) EF: 100 LR: 20-200 ng/mL in PBS	[1 8]
Soy proteins	Soy milk (500 μl)	Fe ₃ O ₄ - Au NPs (12 nm) - 23 mg	grafting of oxidized pAbs on amino- functionalized Au- NPs (cysteamine)	Incubation (15 min, stirring), desorption (5 min, 10% MeOH)	Fluo	RE: 80- 107.3% LR: 1-15 mg/L	[1 9]
Low density lipoprotein	Plas ma (10μl - dilut ed 1/50 0)	Au-NPs (28 nm) - 10 μl, 9.91x10 ⁹ NPs	non-covalent grafting; covalent bonding via amide coupling of mAbs to carboxy terminated- pegylated NPs; oriented immobilization via oxidized carbohydrate moiety of mAb and hydrazide derivatized NP; immobilization via cysteine-tagged proteine A-NPs	Overnight incubation, washing (3 x Tris-HCl, centrifugation), desorption (MeOH + ultrasonication and centrifugation)	LC-MS	RE: 80% (pure media)	[1 7]

182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228

3- Solid phase micro-extraction (SPME) and related techniques

SPME is a miniaturized method that consists in the extraction of compounds from a sample onto a fused silica fiber (100 μm diameter) usually coated by an organic polymer (7-100 μm thickness). Initially developed for the extraction of the volatile compounds from environmental samples before their analysis by gas chromatography (GC), the applications of SPME has been extended to biological fluids with an off-line coupling with liquid chromatography (LC) in most of the cases [21]. Even if the whole automation is not as easy as for the SPME-GC coupling, SPME still provides many advantages by integrating sampling, extraction, and concentration in one-step with an easy transfer of the trapped compounds in an elution solution. The combination of this technique with the high antibodies selectivity that limits the co-extraction of interfering compounds present in complex samples such as biological fluids can constitute an interesting approach to improve the sensitivity of the method.

As reported in Table 2, immunoaffinity SPME (IA-SPME) was developed for the selective extraction of a single target molecule, such as a small drug, *i.e.* theophylline [22], or protein, *i.e.* penicillin binding protein 2a (PBP2a) [23], or a group of structural analogs such as benzodiazepines [24,25], non-steroidal estrogens [26] or quinolones [27]. The extraction of a group of structural analogs takes advantage of the ability of an antibody to recognize the compounds having a strong structural analogy to the antigen used for its production. Since the SPME extraction is followed by the analysis of the extract with a separation method, the individual quantification of each compound is therefore possible.

The preparation of the extraction devices consisted either in immobilizing porous silica particles (5 μm) onto stainless steel devices, followed by the activation of the silica surface by an amino-organosilane ((3-aminopropyl)-triethoxysilane, APTES) and then the use of glutaraldehyde to covalently graft the antibodies by their amino-groups or by direct activation of silica-based material by the same reagents. The dimensions of the final sorbents, usually 1-5 mm diameter and 1.5-3 cm length, are larger than conventional SPME fibers (1cm length silica fiber - 110 μm diameter- coated, polymer - 7-100 μm thickness-) but still considered as miniaturized sorbent while considering the amount of immobilized antibodies. If most of the authors consider that they develop an immunoaffinity SPME method, one of them, that used the biggest device, described its method as immunoaffinity stir bar sorptive microextraction. Nevertheless, the dimensions of these different devices are not so different [27]. IA-SPME consists next in the direct immersion of the sorbent into the sample (Figure 1B) and different parameters can be optimized to extract as much as analytes as possible, such as the extraction time, the stirring speed, the nature and the volume of the desorption solution or the desorption time as for conventional SPME. The final conditions fixed in the different studies are described in Table 2.

For IA-SPME, the nature and amount of immobilized antibodies will also affect the extracted analyte amount. Indeed, it was shown that mAbs gave rise to higher extraction yield of oxazepam than pAbs (with or without a purification step of the pAbs on an oxazepam-based sorbent) and then to a larger linearity range (LR) [25]. However, the use of mAbs necessitates longer equilibrium time that has been explained by the higher affinity of the mAbs. Nevertheless, the amount of immobilized antibodies was not determined in this work [25]. In return, for purified pAbs, giving rise to higher binding capacity than non purified ones, binding

229 capacities from 0.8 [24] to 6.3 pmol [25] of antigen immobilized on 3.1 cm² of sorbent (i.e.
 230 0.26 to 2 pmol/cm² thus corresponding to 59 to 150 ng of purified pAbs/cm²) were reported
 231 while immobilizing directly the antibodies on the silica surface [24,25]. This binding capacity
 232 for the antigen was increased to 49.6 pmol/cm² while grafting mAbs onto silica particles
 233 previously immobilized on stainless still rods [26].
 234 In most of the cases, the extraction and desorption times are about 30 and 20 min,
 235 respectively, as with conventional SPME sorbents. For the application of IA-SPME to the
 236 selective extraction of the PBP2a protein, the conventional desorption procedure using a
 237 solvent was replaced by the direct digestion of the protein by immersing the sorbent in a
 238 trypsin solution [23]. When they were reported, recoveries were between 13 to 67 % with
 239 associated RSD values lower than 14% showing an acceptable repeatability of the whole
 240 analytical procedure applied to trace analysis in complex samples. Concerning the reusability
 241 of the fiber, Yao *et al.* mentioned that it was evaluated once every 3 days for 45 days by
 242 column capacity determination showing a loss of the capacity by a factor 2 during this period
 243 [27]. This is in good agreement with the study of Wang *et al.* that mentioned that after 10 uses
 244 only 58% of the binding capacity remained [26]. They also demonstrated the repeatability of
 245 the preparation of the IA-SPME rods obtaining RSD values below 15% among 6 batches for
 246 each studied estrogen.

247
 248
 249 **Table 2:** Application of immunoaffinity SPME.
 250

Target	Sample	Extraction sorbent	Antibody grafting	Method	Analytical method	Method performance	REF
Theophylline	Serum (diluted with PBS, 1/100, v/v)	silica fiber (1.8 mm, 2.3 cm), silanized with APTES	Covalent grafting of pAbs using GTD	Extraction (3 h), washing (x2)	Liquid scintillation	LR: 10-50 ng/ml	[22]
Benzodiazepines (3)	Urine	borosilicate glass rods (4 mm, 2.5 cm) silanized with APTES	Covalent grafting of pAbs, purified pAbs or mAbs using GTD	Extraction (30 min), desorption (500 µl, MeOH/water)	LC-MS/MS	LR: 0.02-0.5 ng/ml (purified pAbs)	[24,25]
PBP2a (penicillin binding protein 2a)	Standard solution	Stainless steel wires (0.061 in., 1.5 cm) coated with 5 µm porous silica particles silanized with APTES	Covalent grafting of mAbs using GTD	Overnight extraction, several washing steps, trypsin digestion of PBP2a	LC-MS/MS	LOQ: 10 ng/ml	[23]

Non-steroidal estrogens (3)	Environmental waters (1 ml, dilution 1/2)	Stainless steel rods (2 x 18 mm) coated with 5 µm-porous silica particles further silanized with APTES	Covalent grafting of mAbs using GTD	Extraction (30 min), washing (5 s); desorption (1 ml, MeOH, 20 min)	UHPLC-MS/MS	RE:34.2-62.7%, RSD < 14%; LOQ: 0.5 ng/ml	[26]
Quinolones (11)	Bovine milk (centrifuged to remove fat)	Borosilicate glass bars (5 mm, 3 cm) silanized with APTES	Covalent grafting of mAbs using GTD	Extraction (30 min), washing, desorption (900 µl, MeOH/PBS 8/2, 20 min)	LC/Fluo	RE: 13.2-40% (milk), RSD < 12.5% LOQ: 0.2-0.3 ng/g (pure media)	[27]

251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280

4- In-tube solid-phase micro-extraction

Capillary microextraction, also called in-tube SPME (IT-SPME), shows several advantages compared to SPME such as an on-line coupling with separation methods (capillary electrophoresis (CE) and, more frequently, LC). Indeed, with this approach, the analytes are extracted and preconcentrated at the inner surface of a capillary before being desorbed and directly transferred to the separation device (Figure 1C) [15]. Applications of immunoaffinity IT-SPME are reported in Table 3. A method named “immunoaffinity capillary electrophoresis” was described by Phillips and Dickens in 1998 [28]. It consists in the covalent grafting of antibodies fragments (Fabs) at the inner surface of a 100 µm silica capillary. This coating was achieved on approximately 6 cm, the remaining part of the 30 cm-capillary being used for the CE separation. This device was applied to the quantification of recombinant cytokines in human body fluids (urine, plasma, cerebrospinal fluids (CSF), and saliva). Cytokines were labeled directly in the biological fluids and a volume of 30 nl of the sample was next flushed through the capillary leading to the capture of the derivatized cytokines by the immobilized Fabs. A washing step was applied to remove the compounds that were non-specifically trapped such as the matrix interfering compounds and the free fluorophore used for the labelling. Finally, the cytokines were electrophoretically eluted with an acidic buffer. Since this pioneering work, immunoaffinity IT-SPME was coupled on-line with LC-MS and LC-Fluo for the selective analysis of fluoxetine in serum [29] and of interferon α in plasma [30], respectively. For this, the inner surface of a silica capillary of 250 µm i.d. and 60-70 cm length was activated with APTES and grafted with antibodies. This capillary was placed at the loop position of a six-port switching valve and the immunoextraction was achieved by repeated aspirations (draw) and ejections of 50 or 150 µl samples through the capillary. After this, the capillary was eventually washed and the desorption was achieved by passing the LC mobile phase through the immunosorbent (by switching the valve) for the transfer of the analytes to the analytical column. The sample draw/ejection volume and the number of draw/ejection cycles were adapted to the capillary capacity (estimated to 0.92 pmol of target analyte, i.e.

281 fluoxetine) [29] and to the volume comprised between the injection needle and the capillary.
282 Both parameters were optimized together with the flow-rate [29,30] and extraction times
283 between 2.5 to 9 min were fixed.

284 As for other immunoextraction based methods, the maximal amount of analytes that can be
285 extracted without overloading the immunoaffinity capillary strongly depends on the amount
286 of immobilized antibodies. By measuring this maximal amount of antigen that can be retained
287 on the capillary, i.e. 0.92 pmol retained on 5.5 cm², a grafting density of 11 ng/cm² of active
288 pAbs (i.e. about 0.08 pmol/cm²) was estimated [29], which is a very low value. To improve this
289 bonding density, the use of NP-coated capillary was proposed [31,32]. Indeed, polystyrene
290 NPs functionalized with antibodies were immobilized onto the surface of a 250 μm i.d. x 60
291 cm silica capillary for the selective extraction of β2-microglobulin or cystatin C. The
292 performances of this capillary were compared with those obtained by directly immobilizing
293 the antibodies onto the inner wall of the capillary. If the reliability of both system was
294 demonstrated with RSD values of recoveries lower than 5%, the use of NPs allowed to reach
295 a bonding density of about 40 pmol/m antigen, increasing the sorbent capacity by a factor 5
296 [31]. The same group recently proposed to modify first the capillary surface by NPs further
297 functionalized with antibodies that were immobilized with an orientated way (immobilization
298 of the pAbs through the oxidized carbohydrate chain located on their Fc part). The orientation
299 of the antibodies allowed to improve the capacity of the immunosorbent by a factor 3
300 compared to a random immobilization and the use of NPs by a factor 1.5, the highest capacity
301 obtained with oriented immobilization of Abs on NPs being 39 nmol/m of antigen [32].

302 The coating of the surface of a chip channel was also proposed by the group of Woolley to
303 couple IT-SPME on-line with microchip CE [33,34]. For this, a thin film of polymer was
304 photopolymerized on a 0.6 mm-length channel of a chip to be used, after the antibodies
305 coating, as an immunoextraction sorbent before the separation of the target analytes in
306 another channel of the chip. This device was first developed for the trapping of a single
307 molecule, α-fetoprotein (AFP), from human serum thanks to the immobilization of anti-AFP
308 antibodies on the thin film of polymer [33]. Four antibodies specific of four different
309 biomarkers were further simultaneously immobilized in the same way thus enabling the
310 simultaneous extraction of these biomarkers from the same human serum sample, their
311 separation being achieved after their transfer to the separation channel [34]. A low binding
312 density of 0.1 nmol/m² of antibodies (i.e. about 0.01 pmol/cm²) was reported that is close to
313 the one reported for capillary without NPs. Nevertheless, it was considered as sufficient as it
314 allows to reach a linear response up to 500 ng/ml of analyte.

315 Except for two studies reporting overnight extraction, the extraction times reported using
316 capillaries are shorter than those reported in SPME, between 2 and 9 minutes. If the extraction
317 time on chip was still quite long (10 min for the sample percolation and rinsing step on a 6 mm
318 length channel), a short separation time of less than 3 min renders the whole analytical
319 procedure quite fast.

320 Concerning the reusability of such devices, the use of a capillary for more than 200 analyses
321 (spiked buffer) was reported without observing any loss of performance and with RSD < 5%
322 for the same sample on 5 consecutive days [28] or up to 10 times and over 20 days with RSD
323 values lower than 7% for recoveries in plasma sample [30]. The use of orientated
324 immobilization of antibodies also gave rise to a higher stability of the sorbent compared to
325 random immobilization [32]. At last, concerning the repeatability of the preparation of such a
326 sorbent in chip, there was a 7.7 % and 10-30% variability in the amount of retained proteins
327 between different batches of capillary (n=5) [32] or chip (n=3) [34], respectively.

328
329
330

Table 3: Applications of immunoaffinity in-tube SPME

Target	Sample	Extraction sorbent	Antibody grafting	Method	Analytical method	Method performance	REF
Cytokines	Urine, plasma, CSF, saliva (30 nl)	Activated (APTES) silica capillary (6 cm of a 30 cm capillary, 100 μm i.d.)	Fabs from mAbs immobilized using SSMCC	Extraction (2 min), washing, elution (acidic electrolyte)	CE/LIF	LOD: 5-20 ng/ml	[28]
Fluoxetine	Serum (20 x 50 μl)	Activated (APTES) silica capillary (70 cm, 250 μm i.d.)	Covalent grafting of pAbs using GTD	Extraction (20 x 50 μl , 400 $\mu\text{l}/\text{min}$, 2.5 min)	LC-MS	LR: 5-50 ng/ml LOD: 5 ng/ml,	[29]
Interferon α	Plasma (20 x 150 μl)	Activated (APTES) silica capillary (60 cm, 250 μm i.d.)	Covalent grafting of mAbs using GTD	Extraction (20 x 150 μl , 315 $\mu\text{l}/\text{min}$, 9 min)	LC-Fluo	LOQ: 6 IU/ml	[30]
β 2-microglobulin or cystatin C	standard solution	Aldehyde activated-silica capillary (60 cm, 250 μm i.d.)	polystyrene NPs grafted with pAbs using EDC and sulfo-NHS and further immobilized on the silica inner wall	Overnight extraction	PETIA	-	[31]
β 2-microglobulin or cystatin C	standard solution (1 ml inject in 30 min)	APTES-activated silica capillary (60 cm, 250 μm i.d.) grafted with poly(GMA) NPs immobilized via epoxy groups on silica inner wall	Grafting with pAbs on NPs : oriented immobilization via carbohydrate regions on Fc or random immobilization	Overnight extraction	PETIA	RE: 96.8-103.6% (SD < 8%, n=5) in pure media LOQ: 0.5-5 $\mu\text{g}/\text{l}$ (random): 0.5-1 $\mu\text{g}/\text{l}$ (oriented)	[32]
FITC-labeled α -fetoprotein (AFP), four labeled-biomarkers (proteins)	Labeled-human serum (10 μl)	Coating of the PMMA-chip channel with poly(GMA-co-PEGDA) monolith (3 μm thickness, 6 mm)	Covalent grafting of Abs on poly(GMA-co-PEGDA) monolith	Extraction (5 min), washing (5 min), transfer to the separation channel (50-70 s)	CE/LIF on-chip	LR: up to 500 ng/ml; LOQ: \approx ng/ml	[33] [34]

331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377

5- Solid phase extraction on monolith

To increase the amount of Abs immobilized in a reduced size device, the synthesis of a porous monolith followed by the grafting of the antibodies onto this porous support was proposed. This monolith must be hydrophilic to limit the contribution of non-specific hydrophobic interactions during the extraction of the target analytes and must have an accessible function for effective antibody grafting. Monoliths have already been proposed in large formats (50 x 4.6 mm columns or 12 x 3 mm discs) and are not included in this study. For the smaller devices, the monoliths were mainly *in situ* prepared in capillaries from 75 to 250 μm in diameter by polymerization of organic monomers [35–43]. The preparation of hybrid monoliths by hydrolysis and condensation of organosilanes and alkylethoxysilanes (by sol-gel process) has also been proposed [44,45]. These works are summarized in Table 4. These monoliths were synthesized at one end of a long CE capillary (Figure 1D), in a short capillary connected via a switching valve to nanoLC (Figure 1E) or in a short channel of a chip (Figure 1F).

Organic monoliths are considered the easiest to synthesize in a reproducible way and more stable than hybrid monoliths. Most of these monoliths were prepared using GMA as monomer and EGDMA as crosslinking agent. The hydrophilic properties of GMA, which possesses epoxy groups allowing antibody grafting, have often been advanced to justify its use in order to reduce the risk of non-specific interactions by limiting the hydrophobic effect. Nevertheless, for the immunoextraction of a serum protein, glycerylmethacrylate (GMM) was compared and then preferred to GMA to limit this risk [40]. Organosilane-based monoliths are considered to be even more hydrophilic, thus avoiding this type of non-specific interactions. To improve their stability and avoid gel shrinkage, a non-hydrolytic sol-gel process in the presence of ionic liquid at room temperature was reported [44].

The contribution of non-specific interactions in the retention process was particularly studied by groups preparing monoliths. This was certainly motivated by the largest surface of sorbent offered by this approach compared to other devices previously described that can increase this contribution. As an example, it was studied for an organic monolith by measuring the retention of compounds of different polarities [36,41,43] including the antigen [41,42,46] before [43] or after grafting the antibody [37,39,46]. Since antibodies can also develop non-specific interactions, the study of the retention of the target analyte on a monolith grafted with another antibody was also proposed [41,45] as also reported for in-tube SPME [32] and SPME [23]. This last approach appears also useful to optimize the washing step that is supposed to help in reducing non-specific interactions [45]. This contribution of non-specific interactions was studied in detail by Gunasena *et al.*. They reported the screening of different hydrophilic monomers for the development of an IS allowing the trapping of a target protein by limiting both the retention of this target with the monolith by non-specific interactions and the possible interactions of this target with other proteins in the conditions of use of the monolith, the final choice resulting from a compromise [40].

Some parameters such as the synthesis temperature or the quantity and nature of the porogen can affect the permeability of the monolith (which must be sufficient to allow the liquid to flow) and its specific surface area (which must be high to obtain a high number of potential grafting sites and therefore a large extraction capacity). However, promoting permeability which requires large pore size may induce a decrease in the specific surface area, and consequently the capacity. The determination of the capacity was performed by several groups. The entrapping of mAbs in a sol-gel gave rise to a grafting density of 0.1 mg (0.6 nmol)

378 active mAbs/g corresponding to 8% of the introduced antibodies (1.25 mg/g). For a poly-
379 (GMA-EDMA) monolith, the amount of grafted mAbs was 18 mg/g. This sorbent was able to
380 fixed 1.2 pg/cm (3 fmol/cm) of Ochratoxin A thus indicating to the authors that 39% of the
381 randomly immobilized mAbs were active [41]. A higher capacity of 40 µg/cm (40.2 nmol/cm,
382 2.11 nmol/g) of microcystin-LR for a 100 µm i.d. capillary [45] was reported for a hybrid
383 monolith based on APTES and TEOS. This difference is mainly due to the larger specific surface
384 area of silica-based monoliths. This 40 µg/cm capacity of microcystin-LR corresponds to a
385 binding density of 0.543 pmol/µl of active mAbs. This value is 40 times higher than the capacity
386 obtained by direct coating of antibodies on the surface of a capillary [29].


387 In the first studies, these monolithic ISs of 1 to 10 cm in length were applied to the extraction
388 of analytes from standard solutions. A solvent plug was next pushed to desorb the analytes
389 that were either directly detected by LIF through the capillary [35,36,39] or recovered at the
390 end of the capillary and then analyzed by different methods (LC-MS/MS, SDS-PAGE, ICP-MS...)
391 [40,44]. The coupling of the extraction to a separation in CE [41] or nanoLC [45,46] has also
392 been reported more recently.

393 Concerning the introduction of antibodies on chips, their grafting at the inner surface of the
394 injection port of a chip [47,48] and, later, on a glass fiber filter of 2 mm diameter then
395 introduced in the chip port, was proposed by Phillips and Wellner. To improve the sensitivity
396 of the method, the targets extracted from real samples by immunoextraction were further *in*
397 *situ* labelled and analyzed by CE/LIF on chip, thus providing a lab-on-chip device that can be
398 directly applied to real samples [49,50]. After coating the channel surface as previously
399 mentioned, the group of Wooley achieved the *in situ* synthesis of a monolith next grafted with
400 anti-FITC antibodies and used it for the selective extraction of FITC-labelled amino acids or
401 proteins chosen as model molecules [37,38].

402 Despite the fact that monoliths are mainly coupled on-line with the separation or detection
403 steps, the duration of the analyses is very variable, from 20 min to 3 h. In most of the cases,
404 the limiting parameters are the loading mode and the volume of sample that varies from 100
405 pl injected on chip to more than 100 µl. The back-pressure generated by the monolith limits
406 the flow-rate that can be used, the fastest method being obtained by combining on chip the
407 injection of a 100-pl sample with a reduced-size monolith of 2 mm and a CE separation step
408 [38]. However, the sensitivity of the device was poor.

409 Immunoaffinity monoliths (in chip or capillary) were mainly applied to standard solutions. The
410 performances of these miniaturized devices for the analysis of a target molecule in real or
411 complex samples were more rarely described. Among these applications, a 15-cm monolithic
412 IS (in a 180-µm i.d. capillary) grafted with mAbs specific of a protein was applied to the
413 selective trapping of some of its peptides present in a tryptic digest of this protein. The
414 peptides selectively recognized by the mAbs were eluted and transferred to a trap column
415 before being on-line desorbed and transferred to the nanoLC-MS/MS system [46]. This work
416 is an illustration of what could be achieved by immobilizing anti-peptide antibodies as in the
417 SISCAPA approach. In another study, a 100-µm i.d. capillary of a length of 4.5 cm containing a
418 monolithic IS was placed on a 6-ports switching valve and, in this case, directly connected to
419 a nanoLC/UV system[45]. After percolation of an algae extract and application of a washing
420 solution to reduce the non-specific interactions to 8% while ensuring an extraction recovery
421 of 71%, the target analyte, microcystin-LR, was transferred by the LC mobile phase to the
422 reversed phase nanoLC column. Another fully integrated chip device was very recently applied
423 to the simultaneous analysis of two proteins in a human plasma sample, the labeling of the
424 proteins directly in plasma before its introduction on the chip allowing their detection at the

425 nM level [42]. The design and the photograph of the chip, the SEM of the monolith and the
 426 resulting electropherograms, showing again the contribution in terms of selectivity of the Abs,
 427 are reported in Figure 3.
 428



429

430 **Figure 3:** Integrated immunoaffinity extraction and CE in chip for the analysis of protein biomarkers in human
 431 blood serum. Electropherograms of labeled spiked human serum, (A) before and (B) after on-chip immunoaffinity
 432 extraction. Elution/injection times were: (A) 1 min and (B) 15 s. (C) Electropherogram of labeled unspiked human
 433 serum after on chip immunoaffinity extraction and CE. Elution time was 15 s. Design (D) and photograph (E) of
 434 the chip and SEM of a channel cross-section with GMA-EGDMA monolith polymerized inside (F). Adapted from
 435 [42] with permission of the Royal Society of Chemistry.

436

437 Concerning the reusability of the IS monoliths, it was reported that they can be reused up to
 438 50 times without observing any loss of trapping efficiency [46], but some authors observed
 439 losses after 5 [35,41] or even 3 [38] uses. This loss of performance after 3 uses was observed
 440 on 6 monoliths whose performances were similar for the first uses, thus confirming this loss
 441 of performance but also the repeatability of the preparation of the monoliths as reported by
 442 other groups [45,46].

443

444 **Table 4:** Immunoaffinity monolith coupled to CE, nanoLC or integrated on-chip.
 445

Target	Sample	Extraction sorbent	Antibody grafting	Method	Analytical method	Method performance	REF
Fluorescein	Standard solution (750 µl)	sol-gel (DGS/PEG) in a silica capillary (10 cm, 250 µm i.d.)	entrapping of mAbs (DGS/PEG)	Percolation (5 min), washing (10 min) and pulse elution (buffer with 20% MeOH, about 6 min)	Direct LIF detection		[35]

Ochratoxin A	Standard solution	poly(GMA-co-EDMA) monolith in a silica capillary (40 cm, 75 μm i.d.)	covalent grafting (epoxy) of purified pAbs on 8.5 cm	Percolation, washing and pulse elution (85 min)	Direct LIF detection		[36]
FITC-labelled amino acids	Standard solution (100-450 μL)	poly(GMA-co-EDMA) monolith on PMMA chip channel (20 μm x 50 μm x 0.5 cm)	activation with EDA/sulfoS MCC and grafting of reduced pAbs by thiol groups	Percolation (50-225 min), washing and CE elution (20 s)	CE/LIF on-chip	RE: 86% chip-to-chip variability of 3.1% (n=3)	[37]
FITC-labelled proteins	Standard solution (100 μl)	poly(GMA-co-EGDMA) monolith in a PMMA chip; 2mm of monolith in the separation channel	covalent grafting (epoxy) of pAbs	Percolation, elution under voltage in 1 min	CE/LIF on-chip	RE: 92%	[38]
Labeled - testosterone	Standard solution	poly(VDA-co-HEMA-co-EDMA) monolith in a silica capillary (1 cm, 100 μm i.d.)	covalent grafting (through VDA groups) of pAbs	percolation (0.5 min) washing (1 min) and pulse elution (80% MeOH, 1 min)	Direct LIF detection	LOQ: 0.02 mg/l (0.07 μM) RSD: 7.3% (n=4)	[39]
Human IgG	Diluted human serum with PBS (50 μl)	Hybrid monolith (APTES-co-TEOS, PEG, [BMIM]BF ₄) in a silica capillary (80 cm, 530 μm i.d.)	covalently grafted with pAbs using GTD on 10 cm of monolith	Percolation, incubation, washing and pulse elution (80% MeOH); whole procedure in 115 min	Off-line; (MCN)-ICP-MS	RSD on RE of 10.2% and 11.7% for one batch and inter-batch extraction efficiency respectively (n=7) LR: 0.2-10 $\mu\text{g/l}$ LOD: 0.058 $\mu\text{g/l}$ RE: 98 \pm 5% (human serum)	[44]

Haptoglobin	Serum	monoliths of poly(GMM-co-PETA) (diol), poly(GMA-co-EDMA) (epoxy), polyGMM-co-EDMA, aminopropylacrylamide hydrochloride-co-EDMA polymerized in 100 µm i.d. capillary	pAbs immobilized on diol or epoxy based sorbent after their conversion in aldehyde using sodium cyanoborohydride or pAbs and Fab fragments immobilized on amino group using GTD	Percolation, washing and pulse elution pH; whole procedure in 25 min	Off-line; SDS- PAGE or LC-MS/MS		[40]
Ochratoxin A	Standard solution (10 µl)	poly(GMA-co-EDMA) monolith in capillary (8.5 cm, 75 µm i.d.)	covalent grafting (epoxy) of mAbs on 5 cm of monolith	Percolation, washing, elution (short plug of organic solvent before CE separation) (33.5 cm capillary); whole procedure in 2h	CE/LIF	LR: 0.05-250 µg/l RE: 114 ± 11% (n=15)	[41]
Microcystin-LR	Algae extract (150 nl)	Hybrid monolith (APTES-co-TEOS, CTAB, ethanol) in capillary (100 µm i.d.)	Covalent grafting of mAbs on 4.5 cm of monolith using GTD	Percolation and washing (17min); elution by nanoLC mobile phase (10 min)	nanoLC/UV	RE: 70.4-77.6% (RSD: 2.51%, n=6, real samples)	[45]

Labeled - proteins (ferritin, lactoferrin)	Labeled human serum	poly(GMA-co-EGDMA) monolith polymerized in the channel (0.6 mm) of a COC chip activated with PEGdiacrylate	covalent grafting (epoxy) of pAbs	Percolation, washing and elution steps under voltage in 21 min before CE separation on chip (< 1 min)	CE/LIF on chip	LOQ: \approx nM	[42]
Labeled protein (ferritin)	Diluted (x5) human serum	poly(GMA-co-EGDMA) monolith (0.6 mm) prepared in a 3D printed chip (45 μ m x 50 μ m)	covalent grafting (epoxy) of pAbs	Percolation, washing and elution achieved under vacuum	LIF on chip		[43]
Labeled ProGRP digest	human serum digest (20 μ l)	Poly(EDMA-co-VDM) monolith prepared in a capillary (15 cm, 180 μ m i.d.)	covalent grafting (via VDM) of mAbs	loading of the sample (10 min), transfer of the peptides to trap column (5min), LC analysis (12 min)	on line coupling to nanoLC-MS/MS using a trap column	LOD: 520 pg/ml (plasma)	[46]

446
447

6- Conclusions

448 The use of antibodies in the field of analysis and more particularly as a masterpiece of
449 extraction techniques to improve the selectivity of the sample treatment step has been
450 developed for many years. With the miniaturization of the immunosorbents that replaces
451 disposable cartridges or precolumns (packed with conventional particles) by capillaries, chip
452 channels and nanoparticles containing lower amounts of antibodies, the cost of the analytical
453 device should be reduced. However, this requires to develop new approaches for the Abs
454 immobilization by choosing conditions that are efficient in terms of grafting rates but also of
455 the accessibility of antibodies by the antigen. The use of purified polyclonal antibodies in place
456 of monoclonal antibodies, which are more expensive to develop, or antibody fragments that
457 can be grafted in an oriented manner, appears to be a high potential development pathway.
458 Concerning the support for the grafting, the accessibility to large specific surface areas via the

459 use of nanoparticles in dSPE but also in SPME and IT-SPME proves to be an efficient and
460 competitive approach compared to the use of monoliths whose synthesis conditions must
461 ensure large specific surface areas while limiting non-specific interactions as illustrated in this
462 review. Although many proofs of concept have already been proposed, it is nevertheless
463 necessary to complete them for applications with real samples including their validation. At
464 last, fast analysis were expected using miniaturized devices but, as reported in this review,
465 they remain long even for fully integrated devices. This is due to (i) the low levels of
466 concentration that have to be reached requiring large sample volumes to counterbalance the
467 reduced sensitivity of optical detector often used in miniaturized device and (ii) the low
468 permeability of monolith prepared in reduced size diameter devices that generate high back
469 pressures that are difficult to face with existing nanoflow pumping system and that are not
470 always compatible with chip stability.

471

472 **References**

473

- 474 [1] S. Souverain, S. Rudaz, J.L. Veuthey, Restricted access materials and large particle supports
475 for on-line sample preparation: an attractive approach for biological fluids analysis,
476 *Journal of Chromatography B*. 801 (2004) 141–156.
- 477 [2] N. Fontanals, R.M. Marcé, F. Borrull, P.A.G. Cormack, Mixed-mode ion-exchange
478 polymeric sorbents: dual-phase materials that improve selectivity and capacity, *TrAC*
479 *Trends in Analytical Chemistry*. 29 (2010) 765–779. doi:10.1016/j.trac.2010.03.015.
- 480 [3] V. Pichon, Selective sample treatment using molecularly imprinted polymers, *Journal of*
481 *Chromatography A*. 1152 (2007) 41–53.
- 482 [4] A. Sarafray-Yazdi, N. Razavi, Application of molecularly-imprinted polymers in solid-phase
483 microextraction techniques, *TrAC Trends in Analytical Chemistry*. 73 (2015) 81–90.
484 doi:10.1016/j.trac.2015.05.004.
- 485 [5] V. Pichon, F. Brothier, A. Combès, Aptamer-based-sorbents for sample treatment—a
486 review, *Analytical and Bioanalytical Chemistry*. 407 (2015) 681–698.
- 487 [6] M.-C. Hennion, V. Pichon, Immuno-based sample preparation for trace analysis, *Journal*
488 *of Chromatography A*. 1000 (2003) 29–52.
- 489 [7] V. Pichon, Immunoaffinity Extraction, in: *Reference Module in Chemistry, Molecular*
490 *Sciences and Chemical Engineering*, Elsevier, 2016. doi:10.1016/B978-0-12-409547-
491 2.13637-6.
- 492 [8] A. Farjam, J.J. Vreuls, W.J.G.M. Cuppen, U.A.T. Brinkman, G.J. De Jong, Direct introduction
493 of large-volume urine samples into an on-line immunoaffinity sample pretreatment-
494 capillary gas chromatography system, *Anal. Chem.* 63 (1991) 2481–2487.
495 doi:10.1021/ac00021a017.
- 496 [9] J. Płotka-Wasyłka, N. Szczepańska, M. de la Guardia, J. Namieśnik, Modern trends in solid
497 phase extraction: New sorbent media, *TrAC Trends in Analytical Chemistry*. 77 (2016) 23–
498 43. doi:10.1016/j.trac.2015.10.010.
- 499 [10] I. Kohler, J. Schappler, S. Rudaz, Microextraction techniques combined with capillary
500 electrophoresis in bioanalysis, *Anal. Bioanal. Chem.* 405 (2013) 125–141.
501 doi:10.1007/s00216-012-6367-y.
- 502 [11] C.L. Arthur, J. Pawliszyn, Solid phase microextraction with thermal desorption using
503 fused silica optical fibers, *Anal. Chem.* 62 (1990) 2145–2148. doi:10.1021/ac00218a019.

- 504 [12] H. Piri-Moghadam, F. Ahmadi, J. Pawliszyn, A critical review of solid phase
505 microextraction for analysis of water samples, *TrAC Trends in Analytical Chemistry*. 85
506 (2016) 133–143. doi:10.1016/j.trac.2016.05.029.
- 507 [13] T. Khezeli, A. Daneshfar, Development of dispersive micro-solid phase extraction based
508 on micro and nano sorbents, *TrAC Trends in Analytical Chemistry*. 89 (2017) 99–118.
509 doi:10.1016/j.trac.2017.01.004.
- 510 [14] I. Vasconcelos, C. Fernandes, Magnetic solid phase extraction for determination of
511 drugs in biological matrices, *TrAC Trends in Analytical Chemistry*. 89 (2017) 41–52.
512 doi:10.1016/j.trac.2016.11.011.
- 513 [15] Y. Moliner-Martinez, R. Herráez-Hernández, J. Verdú-Andrés, C. Molins-Legua, P.
514 Campíns-Falcó, Recent advances of in-tube solid-phase microextraction, *TrAC Trends in*
515 *Analytical Chemistry*. 71 (2015) 205–213. doi:10.1016/j.trac.2015.02.020.
- 516 [16] M.L. Castillo-García, M.P. Aguilar-Caballos, A. Gómez-Hens, Nanomaterials as tools in
517 chromatographic methods, *TrAC Trends in Analytical Chemistry*. 82 (2016) 385–393.
518 doi:10.1016/j.trac.2016.06.019.
- 519 [17] E. Haller, W. Lindner, M. Lämmerhofer, Gold nanoparticle–antibody conjugates for
520 specific extraction and subsequent analysis by liquid chromatography–tandem mass
521 spectrometry of malondialdehyde-modified low density lipoprotein as biomarker for
522 cardiovascular risk, *Analytica Chimica Acta*. 857 (2015) 53–63.
523 doi:10.1016/j.aca.2014.12.024.
- 524 [18] S. Qiu, L. Xu, Y.-R. Cui, Q.-P. Deng, W. Wang, H.-X. Chen, X.-X. Zhang, Pseudo-
525 homogeneous immunoextraction of epitestosterone from human urine samples based on
526 gold-coated magnetic nanoparticles, *Talanta*. 81 (2010) 819–823.
527 doi:10.1016/j.talanta.2010.01.021.
- 528 [19] M.Á. Molina-Delgado, M.P. Aguilar-Caballos, A. Gomez-Hens, Determination of soy
529 proteins in food samples by dispersive solid-phase immunoextraction and dynamic long-
530 wavelength fluorometry, *Microchimica Acta*. 180 (2013) 1279–1286. doi:10.1007/s00604-
531 013-1056-x.
- 532 [20] T. Le, F.A. Esteve-Turrillas, S. Armenta, M. de la Guardia, G. Quiñones-Reyes, A. Abad-
533 Fuentes, A. Abad-Somovilla, Dispersive magnetic immunoaffinity extraction. Anatoxin-a
534 determination, *Journal of Chromatography A*. 1529 (2017) 57–62.
535 doi:10.1016/j.chroma.2017.10.076.
- 536 [21] T. Kumazawa, X.-P. Lee, K. Sato, O. Suzuki, Solid-phase microextraction and liquid
537 chromatography/mass spectrometry in drug analysis, *Analytica Chimica Acta*. 492 (2003)
538 49–67. doi:10.1016/S0003-2670(03)00680-9.
- 539 [22] H. Yuan, W.M. Mullett, J. Pawliszyn, Biological sample analysis with immunoaffinity
540 solid-phase microextraction, *Analyst*. 126 (2001) 1456–1461. doi:10.1039/B101854J.
- 541 [23] Y. Liu, H. Lord, M. Maciążek-Jurczyk, S. Jolly, M.A. Hussain, J. Pawliszyn, Development
542 of an immunoaffinity solid phase microextraction method for the identification of
543 penicillin binding protein 2a, *Journal of Chromatography A*. 1364 (2014) 64–73.
544 doi:10.1016/j.chroma.2014.08.042.
- 545 [24] H.L. Lord, M. Rajabi, S. Safari, J. Pawliszyn, A study of the performance characteristics
546 of immunoaffinity solid phase microextraction probes for extraction of a range of
547 benzodiazepines, *Journal of Pharmaceutical and Biomedical Analysis*. 44 (2007) 506–519.
548 doi:10.1016/j.jpba.2007.01.040.
- 549 [25] H.L. Lord, M. Rajabi, S. Safari, J. Pawliszyn, Development of immunoaffinity solid phase
550 microextraction probes for analysis of sub ng/mL concentrations of 7-aminoflunitrazepam

551 in urine, *Journal of Pharmaceutical and Biomedical Analysis*. 40 (2006) 769–780.
552 doi:10.1016/j.jpba.2005.10.003.

553 [26] C. Wang, L. Yang, N. Li, X. Zhang, Y. Guo, C. Li, Development of immunoaffinity solid
554 phase microextraction rods for analysis of three estrogens in environmental water
555 samples, *Journal of Chromatography B*. 1061–1062 (2017) 41–48.
556 doi:10.1016/j.jchromb.2017.07.005.

557 [27] K. Yao, W. Zhang, L. Yang, J. Gong, L. Li, T. Jin, C. Li, Determination of 11 quinolones in
558 bovine milk using immunoaffinity stir bar sorptive microextraction and liquid
559 chromatography with fluorescence detection, *Journal of Chromatography B*. 1003 (2015)
560 67–73. doi:10.1016/j.jchromb.2015.09.008.

561 [28] T.M. Phillips, B.F. Dickens, Analysis of recombinant cytokines in human body fluids by
562 immunoaffinity capillary electrophoresis, *ELECTROPHORESIS*. 19 (1998) 2991–2996.
563 doi:10.1002/elps.1150191632.

564 [29] M.E.C. Queiroz, E.B. Oliveira, F. Breton, J. Pawliszyn, Immunoaffinity in-tube solid
565 phase microextraction coupled with liquid chromatography–mass spectrometry for
566 analysis of fluoxetine in serum samples, *Journal of Chromatography A*. 1174 (2007) 72–
567 77. doi:10.1016/j.chroma.2007.09.026.

568 [30] A.R. Chaves, M.E.C. Queiroz, Immunoaffinity in-tube solid phase microextraction
569 coupled with liquid chromatography with fluorescence detection for determination of
570 interferon α in plasma samples, *Journal of Chromatography B*. 928 (2013) 37–43.
571 doi:10.1016/j.jchromb.2013.03.016.

572 [31] B. Xu, S. Cheng, X. Wang, D. Wang, L. Xu, Novel polystyrene/antibody nanoparticle-
573 coated capillary for immunoaffinity in-tube solid-phase microextraction, *Analytical and*
574 *Bioanalytical Chemistry*. 407 (2015) 2771–2775. doi:10.1007/s00216-014-8419-y.

575 [32] L.-L. Ying, Y.-C. Ma, B. Xu, X.-H. Wang, L.-Y. Dong, D.-M. Wang, K. Liu, L. Xu, Poly(glycidyl
576 methacrylate) nanoparticle-coated capillary with oriented antibody immobilization for
577 immunoaffinity in-tube solid phase microextraction: Preparation and characterization,
578 *Journal of Chromatography A*. 1509 (2017) 1–8. doi:10.1016/j.chroma.2017.06.023.

579 [33] W. Yang, X. Sun, H.-Y. Wang, A.T. Woolley, Integrated Microfluidic Device for Serum
580 Biomarker Quantitation Using Either Standard Addition or a Calibration Curve, *Analytical*
581 *Chemistry*. 81 (2009) 8230–8235. doi:10.1021/ac901566s.

582 [34] W. Yang, M. Yu, X. Sun, A.T. Woolley, Microdevices integrating affinity columns and
583 capillary electrophoresis for multibiomarker analysis in human serum, *Lab Chip*. 10 (2010)
584 2527–2533. doi:10.1039/C005288D.

585 [35] R.J. Hodgson, M.A. Brook, J.D. Brennan, Capillary-scale monolithic immunoaffinity
586 columns for immunoextraction with in-line laser-induced fluorescence detection, *Anal.*
587 *Chem*. 77 (2005) 4404–4412. doi:10.1021/ac048142p.

588 [36] K. Faure, N. Delaunay, G. Alloncle, S. Cotte, J.-L. Rocca, Optimization of in-situ
589 monolithic synthesis for immunopreconcentration in capillary, *Journal of Chromatography*
590 *A*. 1149 (2007) 145–150. doi:10.1016/j.chroma.2007.03.031.

591 [37] W. Yang, X. Sun, T. Pan, A.T. Woolley, Affinity monolith preconcentrators for polymer
592 microchip capillary electrophoresis, *ELECTROPHORESIS*. 29 (2008) 3429–3435.
593 doi:10.1002/elps.200700704.

594 [38] X. Sun, W. Yang, T. Pan, A.T. Woolley, Affinity Monolith-Integrated Poly(methyl
595 methacrylate) Microchips for On-Line Protein Extraction and Capillary Electrophoresis,
596 *Analytical Chemistry*. 80 (2008) 5126–5130.

597 [39] H.-X. Chen, T. Huang, X.-X. Zhang, Immunoaffinity extraction of testosterone by
598 antibody immobilized monolithic capillary with on-line laser-induced fluorescence
599 detection, *Talanta*. 78 (2009) 259–264. doi:10.1016/j.talanta.2008.11.004.
600 [40] D.N. Gunasena, Z. El Rassi, Hydrophilic diol monolith for the preparation of immuno-
601 sorbents at reduced nonspecific interactions, *Journal of Separation Science*. 34 (2011)
602 2097–2105. doi:10.1002/jssc.201100353.
603 [41] J. Chamieh, C. Faye, V. Dugas, T. Moreau, O. Vandenabeele-Trambouze, C. Demesmay,
604 Preparation and full characterization of a micro-immunoaffinity monolithic column and its
605 in-line coupling with capillary zone electrophoresis with Ochratoxin A as model solute,
606 *Journal of Chromatography A*. 1232 (2012) 93–100. doi:10.1016/j.chroma.2011.10.061.
607 [42] M. Sonker, E.K. Parker, A.V. Nielsen, V. Sahore, A.T. Woolley, Electrokinetically
608 operated microfluidic devices for integrated immunoaffinity monolith extraction and
609 electrophoretic separation of preterm birth biomarkers, *Analyst*. 143 (2018) 224–231.
610 doi:10.1039/C7AN01357D.
611 [43] E.K. Parker, A.V. Nielsen, M.J. Beauchamp, H.M. Almughamsi, J.B. Nielsen, M. Sonker,
612 H. Gong, G.P. Nordin, A.T. Woolley, 3D printed microfluidic devices with immunoaffinity
613 monoliths for extraction of preterm birth biomarkers, *Analytical and Bioanalytical*
614 *Chemistry*. (2018). doi:10.1007/s00216-018-1440-9.
615 [44] B. Chen, H. Peng, F. Zheng, B. Hu, M. He, W. Zhao, D. Pang, Immunoaffinity monolithic
616 capillary microextraction coupled with ICP-MS for immunoassay with quantum dot labels,
617 *Journal of Analytical Atomic Spectrometry*. 25 (2010) 1674–1681.
618 [45] F. Brothier, V. Pichon, Immobilized antibody on a hybrid organic–inorganic monolith:
619 Capillary immunoextraction coupled on-line to nanoLC-UV for the analysis of microcystin-
620 LR, *Analytica Chimica Acta*. 792 (2013) 52–58. doi:10.1016/j.aca.2013.07.019.
621 [46] M.C.S. Levernæs, O.K. Brandtzaeg, S.F. Amundsen, L. Reubsaet, E. Lundanes, T.G.
622 Halvorsen, S.R. Wilson, Selective Fishing for Peptides with Antibody-Immobilized Acrylate
623 Monoliths, Coupled Online with NanoLC-MS, *Anal. Chem*. 90 (2018) 13860–13866.
624 doi:10.1021/acs.analchem.8b00935.
625 [47] T.M. Phillips, Rapid analysis of inflammatory cytokines in cerebrospinal fluid using chip-
626 based immunoaffinity electrophoresis, *ELECTROPHORESIS*. 25 (2004) 1652–1659.
627 doi:10.1002/elps.200305873.
628 [48] T.M. Phillips, E. Wellner, Measurement of neuropeptides in clinical samples using chip-
629 based immunoaffinity capillary electrophoresis, *Journal of Chromatography A*. 1111
630 (2006) 106–111. doi:10.1016/j.chroma.2006.01.102.
631 [49] T.M. Phillips, E.F. Wellner, Analysis of inflammatory biomarkers from tissue biopsies by
632 chip-based immunoaffinity CE, *ELECTROPHORESIS*. 28 (2007) 3041–3048.
633 doi:10.1002/elps.200700193.
634 [50] E.F. Wellner, H. Kalish, A chip-based immunoaffinity capillary electrophoresis assay for
635 assessing hormones in human biological fluids, *ELECTROPHORESIS*. 29 (2008) 3477–3483.
636 doi:10.1002/elps.200700785.
637
638